Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 11/20 | 0.72 |
| ▸ | AOC3 | Q16853 | 8/20 | 0.72 |
| ▸ | MAOB | P27338 | 7/20 | 0.72 |
| ▸ | MAOA | P21397 | 6/20 | 0.72 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mofegiline SCHEMBL147813 | 0.84 | MAOB (1.00) | AOC2AOC3MAOBMAOADAO | |
| Mofegiline SCHEMBL14005358 | 0.84 | MAOB (1.00) | AOC2AOC3MAOBMAOADAO | |
| Mofegiline SCHEMBL1295041 | 0.84 | MAOB (1.00) | AOC2AOC3MAOBMAOADAO | |
| Mofegiline SCHEMBL1295043 | 0.84 | MAOB (1.00) | AOC2AOC3MAOBMAOADAO | |
| SCHEMBL1294767 | 0.82 | MAOB (0.72) | AOC2AOC3MAOBMAOADAO | |
| Mofegiline SCHEMBL343685 | 0.82 | MAOB (0.96) | AOC2AOC3MAOBMAOADAO | |
| SCHEMBL1295747 | 0.82 | AOC2 (0.72) | AOC2AOC3MAOBMAOADAO | |
| SCHEMBL1296011 | 0.82 | MAOB (0.72) | AOC2AOC3MAOBMAOADAO | |
| SCHEMBL1294750 | 0.82 | AOC2 (0.72) | AOC2AOC3MAOBMAOADAO | |
| SCHEMBL1294745 | 0.82 | AOC2 (0.72) | AOC2AOC3MAOBMAOADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | TOLLESHAUG HELGE | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292547-A1 | Novel Imaging Agents for Fibrosis | LOXL1, LOXL2, LOXL3 | AOC2 468/4885AOC3 366/4885MAOB 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.